DILI Prediction with Human Liver Microtissues

Read the Paper | Learn about the Model | Get Started

 

teaser azgn 01

Comprehensive Study with Genentech and AstraZeneca Confirms Superiority of 3D InSight™ Human Liver Microtissues over 2D PHH for DILI Prediction

A recent Archives of Toxicology article, “Utility of spherical human liver microtissues for prediction of clinical drug-induced liver injury” by Proctor et al. (2017), highlights the advantages of using 3D InSight™ Human Liver Microtissues (3D hLiMT) for DILI prediction. Here's a brief summary of the paper.

Study objective
Systematic validation of 3D hLiMT vs. 2D PHH for their predictive value in discriminating between known hepatotoxicants and clinically safe drugs

Study design
The study tested a panel of 110 clinically known drugs on 2D PHH and 3D hLiMT utilizing the same hepatocyte lot, compound concentrations and endpoint (ATP-content)

Key findings about 3D hLiMT

hLiMt sensitivity 01
  •  2-fold more sensitive in identifying known hepatotoxicants in comparison to 2D PHH (sensitivity of e.g. 60.9% vs. 33.3%)
  • Specificity for prediction of non-DILI drugs remained very high, even after 14 days of compound exposure
  • Assessment of novel hepatic injury biomarkers, such as miRNA122, HMGB1 and α-GST 

 

About the data

  • AstraZeneca and Genentech chose the validation compound set to be representative of a “real-world” situation. In order to conduct a truly independent assessment of the model, all 3D studies were performed at InSphero under conditions where the identities of the 110 compounds were blinded, and all 2D studies were conducted independently by Genentech.
  • The compound set included some with limited solubility, as well as many weak DILI compounds with known rare and late DILI onset. For example, out of the 21 DILI compounds where no IC50 value was determined, 14 compounds were only tested at less than 20-fold of the patients’ plasma concentrations due to solubility issues, thus preventing calculations of margin-of-safety.
  • Four drugs (Stavudine, Methotrexate, Dantrolene, Nifedipine) were only toxic in vivo after several months of administration, and another drug (Trovafloxacin) is known to cause DILI in an idiosyncratic reaction, i.e., in the presence of inflammation, thus requiring different stimuli. Trovafloxacin toxicity was, however, correctly detected in the presence of an inflammatory stimulus.

About the model
Power_of_3D_InSight_Liver_Microtissues

Organotypic 3D InSight™ Human Liver Microtissues feature:

  • Polarized hepatocytes with active hepatobiliary bile-salt secretion (BSEP and MRP2) and presence of bile canaliculi
  • Preserved cytochrome P450 activity over the 14-day assay period
  • 6-fold increase in mitochondrial spare respiratory capacity compared to 2D PHH3
  • Incorporation of inflammation-sensing Kupffer cells for detection of indirect effects on liver function

Displaying > 28-day in vitro longevity and more physiologically relevant biology, 3D InSight™ Human Liver Microtissues enable cumulative assessment of the most important factors driving DILI in vivo:

  • Long-term drug exposure
  • Active drug metabolism
  • BSEP inhibition
  • Mitochondrial impairment

 Read the Paper

AZ Gen Paper thumb 01

Learn how you can improve sensitivity for DILI prediction by employing long-term drug exposure

Guaranteed viability for 28 days in most of our liver models allows highly reproducible assessment of both chronic and short-term drug exposure without the use of animals.

Arch Toxicol. | 2017 Jun 13. doi: 10.1007/s00204-017-2002-1

 


Get Started

Upgrade your DILI prediction model and de-risk with confidence. To help you get started with 3D InSight™ Human Liver Microtissues for DILI Prediction, we offer a kit and a service designed to enable you to quickly assess the benefits of our model and integrate 3D microtissues into your safety testing workflow.

Find out how you can detect and predict DILI earlier in your testing workflow.

This email address is being protected from spambots. You need JavaScript enabled to view it.

Company video

company-video-inspheor